IGF-1 LR3 vs Ipamorelin
IGF-1 LR3 and Ipamorelin are studied in overlapping research areas, which is why they are frequently compared. This is a neutral side-by-side reference drawn from published preclinical literature and laboratory handling data.
How they actually differ
Comparing the two: IGF-1 LR3 is recombinant 83-residue protein analogue of igf-1, while Ipamorelin is synthetic pentapeptide gh secretagogue (ghrelin-receptor agonist) — different molecular classes with different handling consequences; they call for different primary diluents (dilute acetic acid (0.1 m) or 10 mm hcl — required for initial dissolution versus bacteriostatic water (0.9% benzyl alcohol)); their leading degradation routes differ (denaturation and aggregation for IGF-1 LR3, c-terminal amide hydrolysis over long solution storage. for Ipamorelin), so the storage precautions that matter are not the same; their practical working windows differ once reconstituted. The sections below set out each in full.
IGF-1 LR3 — origin
IGF-1 LR3 is an engineered analogue carrying two changes to native IGF-1: an arginine substitution at position 3 and a 13-residue N-terminal extension. The Arg3 substitution is the functional one — it drastically reduces binding to IGF binding proteins, which normally sequester the great majority of circulating IGF-1. The result is a molecule that stays free rather than bound.
Ipamorelin — origin
Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a pentapeptide ghrelin-receptor agonist. It was characterised as the first highly selective growth-hormone secretagogue — prompting GH release with minimal effect on cortisol, prolactin or appetite signalling, which is the property that keeps it in the research literature.
IGF-1 LR3 research themes
The Arg3 substitution reduces binding-protein affinity, which is the entire design rationale.
Widely used in cell-culture research as a growth-factor supplement.
Studied in muscle-biology research models.
The canonical downstream pathway examined in IGF-1 receptor research.
Ipamorelin research themes
Studied as a selective GHS-R agonist that releases GH with little effect on cortisol, prolactin or ACTH — the feature that distinguishes it from earlier GHRPs.
Examined for the shape and timing of growth-hormone release in research models.
Frequently combined with GHRH analogues such as CJC-1295 to study two GH-release pathways at once.
IGF-1 LR3 handling
- Dissolve in dilute acetic acid or dilute HCl FIRST; do not attempt direct dissolution in water or PBS.
- Add carrier protein (e.g. 0.1% BSA) for storage of dilute solutions to prevent adsorptive loss.
- Prepare single-use aliquots — freeze–thaw denaturation is irreversible.
- Do not vortex; agitation denatures folded proteins at the air–liquid interface.
Ipamorelin handling
- Reach room temperature before opening.
- Swirl to dissolve; the peptide clears in seconds.
- Label aliquots with reconstitution date and diluent.
Both third-party tested
Every Popular Peptides batch of IGF-1 LR3 and Ipamorelin is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.
IGF-1 LR3 reference
Related comparisons
IGF-1 LR3 and Ipamorelin are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.